Icatibant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Icatibant
Icatibant.png
Systematic (IUPAC) name
(2S)-2-[[(3aS,7aS)-1-[2-[(2S)-2-[[(2S)-
2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)
pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-
2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-
3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]
3,4-dihydro-1H-isoquinoline-3-carbonyl]
2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-
5-(diaminomethylideneamino)pentanoic acid
Clinical data
Trade names Firazyr
AHFS/Drugs.com International Drug Names
Licence data EMA:Link, US FDA:link
Pregnancy cat.
Legal status
Routes subcutaneous
Identifiers
CAS number 130308-48-4 N
ATC code B06AC02
PubChem CID 71364
IUPHAR ligand 667
DrugBank DB06196
ChemSpider 16736634 YesY
UNII 7PG89G35Q7 YesY
ChEBI CHEBI:68556 N
ChEMBL CHEMBL1743581 N
Chemical data
Formula C59H89N19O13S 
Mol. mass 1304.52 g/mol
 N (what is this?)  (verify)

Icatibant (trade name Firazyr) is a peptidomimetic drug consisting of ten amino acids, which is a selective and specific antagonist of bradykinin B2 receptors. It has been approved by the European Commission for the symptomatic treatment of acute attacks[1][2] of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency.

Mode of action[edit]

Bradykinin is a peptide-based hormone that is formed locally in tissues, very often in response to a trauma. It increases vessel permeability, dilates blood vessels and causes smooth muscle cells to contract. Bradykinin plays an important role as the mediator of pain. Surplus bradykinin is responsible for the typical symptoms of inflammation, such as swelling, redness, overheating and pain. These symptoms are mediated by activation of bradykinin B2 receptors. Icatibant acts as a bradykinin inhibitor by blocking the binding of native bradykinin to the bradykinin B2 receptor.

Regulatory status[edit]

Icatibant has received orphan drug status in Australia, EU, Switzerland and US for the treatment of angiotensin-converting-enzyme inhibitor (ACE-1) induced angioedema (HAE).

In the EU, the approval by the European Commission (July 2008) allows Jerini to market Firazyr in the European Union's 27 member states, as well as Switzerland, Lichtenstein and Iceland, making it the first product to be approved in all EU countries for the treatment of HAE.[1] In the US, the drug was granted FDA approval on August 25, 2011.[3]

See also[edit]

References[edit]